Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02073994 · ClinicalTrials.gov registry record · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT02073994: Completed Phase 1 study, sponsored by Institut de Recherches Internationales Servier.
NCT02073994 is a Phase 1 study that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 174 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (190% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02073994, a Phase 1 study, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four arms of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Anticipated time on study treatment is until disease progression, unacceptable toxicity occurs or at Investigator discretion.
Interventions
- DRUG AG-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2024-01-04 |
| Phase | Phase 1 |
What the finished NCT02073994 record still lists
NCT02073994 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (190% higher).
The record links to 0 conditions, and to 1 intervention - of which AG-120 is the first listed.
NCT02073994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02073994 about?
NCT02073994 is a clinical study titled "Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation". The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients w...
What is the current status of trial NCT02073994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2014-03-01. Estimated completion is 2024-01-04.
What interventions are being tested in trial NCT02073994?
The interventions under investigation include: AG-120 (DRUG).
Who is sponsoring clinical trial NCT02073994?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02073994's enrollment target sits among peer trials
174 322nd of 2000 higher than 1,677 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI